ATE372350T1 - Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften - Google Patents

Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften

Info

Publication number
ATE372350T1
ATE372350T1 AT99955483T AT99955483T ATE372350T1 AT E372350 T1 ATE372350 T1 AT E372350T1 AT 99955483 T AT99955483 T AT 99955483T AT 99955483 T AT99955483 T AT 99955483T AT E372350 T1 ATE372350 T1 AT E372350T1
Authority
AT
Austria
Prior art keywords
cell
target cell
molecule
complex
hla class
Prior art date
Application number
AT99955483T
Other languages
English (en)
Inventor
Philip Savage
Original Assignee
Alexis Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812227.8A external-priority patent/GB9812227D0/en
Application filed by Alexis Biotech Ltd filed Critical Alexis Biotech Ltd
Application granted granted Critical
Publication of ATE372350T1 publication Critical patent/ATE372350T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99955483T 1998-06-05 1999-06-04 Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften ATE372350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812227.8A GB9812227D0 (en) 1998-06-05 1998-06-05 Novel method
GB9908333A GB2339782A (en) 1998-06-05 1999-04-12 Chimeric protein complexes comprising HLA class I antigens

Publications (1)

Publication Number Publication Date
ATE372350T1 true ATE372350T1 (de) 2007-09-15

Family

ID=26313811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955483T ATE372350T1 (de) 1998-06-05 1999-06-04 Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften

Country Status (14)

Country Link
US (1) US7268219B1 (de)
EP (1) EP1093465B1 (de)
JP (1) JP4587566B2 (de)
AT (1) ATE372350T1 (de)
AU (1) AU770596B2 (de)
CA (1) CA2332642C (de)
CY (1) CY1106948T1 (de)
DE (1) DE69937055T2 (de)
DK (1) DK1093465T3 (de)
ES (1) ES2292259T3 (de)
GB (2) GB2339782A (de)
IL (2) IL139950A0 (de)
PT (1) PT1093465E (de)
WO (1) WO1999064464A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001090198A1 (en) * 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB0426903D0 (en) * 2004-12-08 2005-01-12 Alexis Biotech Ltd Complexes and methods
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CN106282237A (zh) * 2015-05-27 2017-01-04 北京大学 一种biotin-avidin-慢病毒表达载体和CAR-T细胞制备方法及可视化方案
GB201609380D0 (en) * 2016-05-27 2016-07-13 Savage Philip M HLA Targeting
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5026785A (en) * 1989-05-12 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
WO1996004314A1 (en) * 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens

Also Published As

Publication number Publication date
GB2339782A (en) 2000-02-09
ES2292259T3 (es) 2008-03-01
PT1093465E (pt) 2007-09-24
DE69937055D1 (de) 2007-10-18
WO1999064464A2 (en) 1999-12-16
WO1999064464A3 (en) 2000-02-03
CA2332642C (en) 2010-01-05
JP4587566B2 (ja) 2010-11-24
EP1093465A2 (de) 2001-04-25
CY1106948T1 (el) 2012-09-26
GB2355983B (en) 2002-08-14
US7268219B1 (en) 2007-09-11
GB9908333D0 (en) 1999-06-09
AU770596B2 (en) 2004-02-26
DE69937055T2 (de) 2008-05-29
JP2002517517A (ja) 2002-06-18
CA2332642A1 (en) 1999-12-16
IL139950A (en) 2009-06-15
GB2355983A (en) 2001-05-09
EP1093465B1 (de) 2007-09-05
AU4276799A (en) 1999-12-30
IL139950A0 (en) 2002-02-10
DK1093465T3 (da) 2008-01-07
GB0029565D0 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
ATE372350T1 (de) Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften
Afonina et al. Mosses of the Russian Arctic: check-list and bibliography
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
SI1427817T1 (sl) Razmnoževanje virusov in celičnih kultur
ATE289348T1 (de) Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
Kim et al. A western Eurasian male is found in 2000‐year‐old elite Xiongnu cemetery in Northeast Mongolia
HK1052301A1 (zh) α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
DE60234115D1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
HUP0100352A2 (hu) Mycobacterium vaccaeből származó kompozíciók és eljárások ezek alkalmazására
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
DE69520943T2 (de) Malariapeptide
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
AU2003226884A1 (en) Immunoglobulin igg3 as a marker for protecting against infectious viral diseases, and the uses of the same
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
WO2004078926A3 (en) Immunologigal markers
GB0227274D0 (en) Probes
AU2001230204A1 (en) Tumor and senescence marker
Horaud Viral vaccines and cell substrate: a “historical” debate
Brandis , GP Talwar (Ed.) Progress in Vaccinology.(Progress in Vaccinology, Vol. 2), XX, Springer-Verlag, Berlin-Heidelberg-New York (1989), 483 pages, 77 illustrations., Hard cover DM 298.-

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1093465

Country of ref document: EP

REN Ceased due to non-payment of the annual fee